Eurofins Genoma Srl (Genoma), a wholly-owned subsidiary of Eurofins Scientific (EUFI.PA), is proud to introduce GeneSafe, the first non-invasive prenatal test (NIPT) that screens for both de novo (gene mutations that are not inherited) and inherited single-gene disorders. Eurofins Genoma, one of the leading specialty diagnostics testing providers in Italy, is a pioneer of NIPT and leads the industry in innovative diagnostic tests in oncology.
Currently, NIPTs available in the market only screen for aneuploidies and microdeletions. Genoma’s own PrenatalSafe Karyo also screens for rare aneuploidies and segmental chromosome imbalances in every chromosome in the fetal genome. GeneSafe goes much further, identifying fetal conditions that could be missed by traditional prenatal testing. It detects over 40 severe genetic disorders that may occur in the absence of any family history of the condition. Furthermore, GeneSafe is now the first NIPT to detect disorders with an increased prevalence associated with advanced paternal age.
Nowadays, later-stage parenthood is increasingly common, particularly in developed countries. GeneSafe is simple, requiring only a small blood sample, and completely safe, posing no risks for the fetus. In addition, it is extremely reliable and very fast, with a turnaround time of only 10 days. It works as a complementary screen to traditional NIPT, providing a more complete picture of the risk of a pregnancy being affected by a genetic disorder. Eurofins Genoma will be launching GeneSafe in the upcoming weeks and is constantly working to further expand the number of genetic disorders that their tests are able to detect.
Comment from Dr. Gilles Martin, Eurofins CEO: “The acquisition of Genoma, in June of this year, has been very beneficial in expanding Eurofins’ testing portfolio in the specialty clinical diagnostics market. Their long history of innovation in genetic testing has, once again, been reinforced with the introduction of GeneSafe. This new test, while providing previously unavailable insights to expecting mothers and medical practitioners working with Genoma, will also be made available to those served by Eurofins’ clinical diagnostics companies around the world, including Biomnis, Megalab, Lifecodexx as well as Eurofins’ subsidiaries in Asia. This is a clear demonstration of the benefits that Eurofins’ growing network of clinical genetics laboratories can provide to patients and healthcare professionals globally.”
Eurofins genoma introduces, non-invasive prenatal test, genesafe
3.png)
6.jpg)